浙江省2022—2023年血液肿瘤患儿化疗后血清破伤风抗体水平调查
该研究纳入2022年1月至2023年12月浙江大学医学院附属儿童医院293例15岁以下血液肿瘤患儿为病例组,匹配293名同年龄社区健康儿童为对照组,检测化疗前、化疗后1个月及对照组破伤风IgG抗体水平。结果显示化疗后1个月抗体阳性率和几何平均浓度均显著低于化疗前及对照组,提示化疗后破伤风抗体水平下降。
要点
- 血液肿瘤患儿化疗后1个月破伤风IgG抗体阳性率70.99%,低于化疗前84.64%和对照组84.98%。
- 化疗后破伤风IgG抗体几何平均浓度为0.73±0.11 IU/ml,低于化疗前1.22±0.17 IU/ml和对照组1.06±0.06 IU/ml。
- 化疗后破伤风抗体水平下降且低于健康人群,提示需评估化疗后再次接种含破伤风成分疫苗的必要性。
核心结论
- 肿瘤患儿化疗后1个月破伤风IgG抗体水平较化疗前下降,且低于健康人群。
研究设计与样本
- 病例组为2022年1月至2023年12月浙江大学医学院附属儿童医院住院的293例15岁以下血液肿瘤患儿,对照组为匹配的293名同年龄社区健康儿童。
- 检测病例组化疗前、化疗后1个月及对照组的破伤风IgG抗体水平,采用χ²检验和t检验比较抗体阳性率及几何平均浓度。
主要发现
- 病例组化疗后1个月破伤风IgG抗体阳性率70.99%,显著低于化疗前84.64%(χ²=73.10,P<0.001)及对照组84.98%(χ²=16.72,P<0.001)。
- 化疗后破伤风IgG抗体几何平均浓度0.73±0.11 IU/ml,显著低于化疗前1.22±0.17 IU/ml(t=4.61,P<0.001)及对照组1.06±0.06 IU/ml(t=1.98,P=0.048)。
- 两组男女性别比分别为1.24∶1和1.20∶1,平均年龄分别为(6.66±3.66)岁和(6.94±3.73)岁。
临床怎么用
- 对血液肿瘤化疗后患儿应关注破伤风抗体水平下降,评估再次接种含破伤风成分疫苗的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To dynamically monitor changes in the levels of serum tetanus antibody in children with hematological malignancies before and after chemotherapy, and to evaluate the necessity of re-vaccination with tetanus-toxoid-containing vaccine (TTCVs) post-chemotherapy. A total of 293 children under 15 years old with hematological malignancies hospitalized in the Children's Hospital affiliated with the School of Medicine at Zhejiang University from January 2022 to December 2023 were included as the case group, matched with 293 community-based healthy children of the same age as the control group. The level of tetanus IgG antibody was measured in the case group pre-chemotherapy and 1 month post-chemotherapy, as well as in the control group. The χ² test and t-test were used to compare the differences in the positive rate and geometric mean concentration (GMC) of tetanus IgG antibody among groups. The male-to-female ratios were 1.24∶1 and 1.20∶1, and the mean ages were (6.66±3.66) years and (6.94±3.73) years for the two groups, respectively. The positive rate of tetanus IgG antibody post-chemotherapy (70.99%) was significantly lower than that pre-chemotherapy (84.64%) (χ²=73.10, P<0.001), and also significantly lower than that in the control group (84.98%) (χ²=16.72, P<0.001). The GMC of tetanus IgG antibody post-chemotherapy (0.73±0.11 IU/ml) was significantly lower than that pre-chemotherapy (1.22±0.17 IU/ml) (t=4.61, P<0.001). It was also significantly lower than that of the control group (1.06±0.06 IU/ml) (t=1.98, P=0.048). In conclusion, the level of tetanus IgG antibody in children with tumors 1 month post-chemotherapy decreases compared with that pre-chemotherapy and is lower than that in the healthy population. 动态监测血液肿瘤患儿化疗前后血清破伤风抗体水平变化,评估化疗后再次接种含破伤风成分疫苗(TTCVs)的必要性。纳入2022年1月至2023年12月在浙江大学医学院附属儿童医院住院治疗的293例15岁以下血液肿瘤患儿为病例组,匹配293名同年龄社区健康儿童为对照组,检测病例组患儿化疗前、化疗后1个月及对照组破伤风IgG抗体水平,采用χ²检验和t检验比较各组间抗体阳性率及滴度水平差异。2组男女性别比分别为1.24∶1和1.20∶1;年龄为(6.66±3.66)岁和(6.94±3.73)岁。病例组化疗后1个月破伤风IgG抗体阳性率(70.99%)显著低于化疗前(84.64%)(χ²=73.10,P<0.001)及对照组(84.98%)(χ²=16.72,P<0.001);化疗后破伤风IgG抗体几何平均浓度[(0.73±0.11)IU/ml]显著低于化疗前[(1.22±0.17)IU/ml](t=4.61,P<0.001)及对照组[(1.06±0.06)IU/ml](t=1.98,P=0.048)。综上,肿瘤患儿化疗后1个月破伤风IgG抗体水平较化疗前下降,且低于健康人群。.
引用
- Xu YY, Ji C, Shen HP, et al. [Survey on serum tetanus antibody levels in children with hematological malignancies post-chemotherapy in Zhejiang Province from 2022 to 2023]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 42893916. doi:10.3760/cma.j.cn112150-20251020-01007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。